Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomibuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomibuvir SCHEMBL15893235 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL101462 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL17856953 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL134168 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| Lomibuvir SCHEMBL134631 | 1.00 | NR1I2 (0.66) | NR1I2CYP2E1 | |
| SCHEMBL12949713 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15233239 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498203 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498324 | 0.97 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL12433104 | 0.95 | NR1I2 (0.63) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235703-A1 | THIOPHENE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235705-A1 | FORMULATIONS OF THIOPHENE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130183266-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235705-A1 | FORMULATIONS OF THIOPHENE COMPOUNDS | TPMT, NAT1, TST | NR1I2 1643/4885CYP2E1 54/4885 |
| US-20140235703-A1 | THIOPHENE COMPOUNDS | MAP3K1, MAPK1, PEAK1 | NR1I2 1415/4885CYP2E1 6/4885 |
| US-20130183266-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, CEL, HAVCR2 | NR1I2 1026/4885CYP2E1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.